Medicenna Presents at National Brain Tumor Society's Research Round Table
July 25, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
Medicenna's President and CEO, Dr. Fahar Merchant, was invited to participate and present at the Brain Cancer Research Roundtable organized by the National Brain Tumor Society (“NBTS”)The focus of the...
Medicenna Extends Period to Exercise Certain Warrants
July 05, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced...
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
June 27, 2023 08:00 ET
|
Medicenna Therapeutics Corp.
MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response continuing for over 40 weeks and stable disease for over 70 weeks as a...
Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
April 27, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, April 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 18, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced...
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
April 17, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
-- IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2, which is overexpressed in many solid tumors but minimally expressed in normal tissues --...
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study
March 30, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts - Continued tumor reduction and complete...
Medicenna Announces Upcoming Presentation at the AACR Annual Meeting
March 15, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today...
Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today...
Medicenna Establishes At-the-Market Sales Facility
February 17, 2023 17:16 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced...